[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540367":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":40,"locations":44,"responsibleParty":46,"collaborators":49,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":44,"enrollmentInfo":63,"targetDuration":44,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":74,"whyStopped":44,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":44},{"fullName":5,"class":6},"Oman Medical Speciality Board","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Parecoxib","EXPERIMENTAL","40mg of IV Parecoxib",[13],"Drug: Parecoxib",{"label":15,"type":16,"description":17,"interventionNames":18},"Morphine","ACTIVE_COMPARATOR","5 mg of IV Morphine",[19],"Drug: Morphine",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Single dose of 40mg of IV Parecoxib.",[9],[26],"a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID)",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Single dose of 5 mg of IV Morphine.",[15],[31],"Morphine Sulfate",[33,37],{"name":34,"affiliation":35,"role":36},"USAMA ALKHALASI, MD","Armed Forces Hospital, Oman","STUDY_CHAIR",{"name":38,"affiliation":35,"role":39},"Muzna Al Sawafi, MD","PRINCIPAL_INVESTIGATOR",[41],{"name":34,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","+96894094001",null,"u.alkhalasi@gmail.com",{"type":39,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Usama Al-Khalasi","EM Specialist",[50],{"name":35,"class":51},"UNKNOWN","100540367","phase-3-analgesic-effect-of-parecoxib-versus-morphine-in-scd-patients-presenting-to-the-emergency-department-100540367",false,"NCT06315920","Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department","Parecoxib Versus Morphine in Acute Pain Management for Sickle Cell Disease Patients in Emergency Department: a Randomized Controlled Trial.","PASC","Inclusion Criteria:\n\n* An adult (\\>18 years) sickle cell disease patient presents with moderate-severe vaso-occlusive crisis (VOC) to the ED.\n\nExclusion Criteria:\n\n* Non-VOC Pain (e.g. Acute chest syndrome, sequestration, septic arthritis, Etc.)\n* Weight less than 50 KG\n* Recurrent visits \\> one visit\u002F week\n* Opioids within 24hrs\n* NSAIDs within 24hrs\n* Contraindications to NSAIDs (e.g. allergy, Asthma, CKD, pregnancy, Etc.)\n* Lactating mothers\n* Visited another health institution within 24hrs",true,"ALL","18 Years",{"count":64,"type":65},226,"ESTIMATED","INTERVENTIONAL",[68],"PHASE3","Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia.\n\nObjectives:\n\nPrimary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises.\n\nSecondary: Reduce opioid use\u002Fdependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib.\n\nMethodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups.\n\nIntervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned.\n\nExpected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.",[71],"Sickle-Cell Disease with Crisis",[73],"SCD, Parecoxib , Opioids","NOT_YET_RECRUITING","2025-03-17",{"date":77,"type":78},"2025-03-20","ACTUAL",{"date":80,"type":65},"2026-05-01",{"date":82,"type":65},"2028-07-01",{"name":5,"class":6}]